Boehringer Ingelheim Opens Commercial-Scale Manufacturing Site in China
Boehringer Ingelheim has inaugurated its commercial production site for biopharmaceuticals in Zhang Jiang Hi-tech Park in Shanghai, China. The site, with first-phase investment of more than EUR 70 million ($78 million), uses mammalian cell-culture technology and will support the company’s contract manufacturing business.
Boehringer Ingelheim said it has made this move with the long-term goal to become a leader for contract development and manufacturing of monoclonal antibodies and recombinant proteins in China. Since 2014, Boehringer Ingelheim China Biopharmaceuticals has been operating its GMP clinical material supply at 100-L and 500-L scales. After its inauguration, the facility will operate for clinical and commercial supply on a 2000-L single-use bioreactor scale. It is designed to flexibly add additional 2000-L single-use bioreactors and fill/finish capabilities.
The company has biopharmaceutical production sites in: Biberach, Germany; Vienna, Austria; Fremont, California; and now Shanghai to support its contract manufacturing business.
Source: Boehringer Ingelheim